Duration of neutralizing antibody titer after Japanese encephalitis vaccination

Microbiology and Immunology

Volumn 51, Issue 6, 2007, Pages 609-616

  Abe, Motoharu ^a   Okada, Kenji ^b   Hayashida, Kenshi ^a   Matsuo, Fujio ^a   Shiosaki, Kouichi ^a   Miyazaki, Chiaki ^c   Ueda, Kohji ^d   Kino, Yoichiro ^a  

^a Kaketsuken   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c Fukuoka West Rehabilitation Center for Children   (Japan)

^d Seinan Jo Gakuin University   (Japan)

Author keywords

Duration of neutralizing antibody titer; Japanese encephalitis vaccine; Japanese encephalitis virus; Routine vaccination in Japan

Indexed keywords

ENCEPHALITIS VACCINE; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; EPIDEMIC ENCEPHALITIS; HUMAN; TREATMENT INDICATION; VACCINATION;

JAPANESE ENCEPHALITIS VIRUS;

EID: 34250814434     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2007.tb03947.x     Document Type: Article

References (29)

1. Abe, M., Kuzuhara, S., and Kino, Y. 2003. Establishment of an analyzing method for a Japanese encephalitis virus neutralization test in Vero cells. Vaccine 21: 1989-1994.
2. Abe, M., Shiosaki, K., Hammar, L., Sonoda, K., Xing, L., Kuzuhara, S., Kino, Y., and Cheng, R.H. 2006. Immunological equivalence between mouse brain-derived and Vero cell-derived Japanese encephalitis vaccines. Virus Res. 121: 152-160.
3. Centers for Disease Control and Prevention. 1993. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 42 (No. RR-1): 1-15.
4. Coursaget, P., Yvonnet, B., Gilks, W., Wang, C., Day, N., Chiron, J., and Diop-Mar, I. 1991. Scheduling of revaccination against hepatitis B virus. Lancet 337: 1180-1183.
5. Goodwin, K., Viboud, C., and Simonsen, L. 2006. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24: 1159-1169.
6. Halstead, S.B., and Tsai, T.F. 2004. Japanese encephalitis vaccines, p. 919-958. In Plotkin, S.A., and Orenstein, W.A. (eds), Vaccines, 4th ed, WB Saunders, Philadelphia, PA.
7. Hombach, J., Barrett, A.D., Cardosa, M.J., Deubel, V., Guzman, M., Kurane, I., Roehrig, J.T., Sabchareon, A., and Kieny, M.P. 2005. Review on flavivirus vaccine development. Proceedings of a meeting jointly organized by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine 23: 2689-2695.
8. Hombach, J., Solomon, T., Kurane, I., Jacobson, J., and Wood, D. 2005. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23: 5205-5211.
9. Kitano, T., and Oya, A. 1996. Japanese encephalitis vaccine, p. 103-113. In Arai, Y., Asano, T., Chino, F., Katow, S., Miyamura, T., Nakamura, R., Oya, A., and Sato, H. (eds), Vaccine handbook, Maruzen, Tokyo.
10. Kurane, I., and Takasaki, T. 2000. Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains. Vaccine 18 Suppl 2: 33-35.
11. Kuwayama, M., Ito, M., Takao, S., Shimazu, Y., Fukuda, S., Miyazaki, K., Kurane, I., and Takasaki, T. 2005. Japanese encephalitis virus in meningitis patients, Japan. Emerg. Infect. Dis. 11: 471-473.
12. Kuzuhara, S., Nakamura, H., Hayashida, K., Obata, J., Abe, M., Sonoda, K., Nishiyama, K., Sugawara, K., Takeda, K., Honda, T., Matsui, H., Shigaki, T., Kino, Y., Mizokami, H., Tanaka, M., Mizuno, K., and Ueda, K. 2003. Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine 21: 4519-4526.
13. Mackenzie, J. 2005. Emerging zoonotic encephalitis viruses: lessons from Southeast Asia and Oceania. J. Neurovirol. 11: 434-440.
14. Mackenzie, J.S., Gubler, D.J., and Petersen, L.R. 2004. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10: S98-109.
15. Mackenzie, J.S., Johansen, C.A., Ritchie, S.A., van den Hurk, A.F., and Hall, R.A. 2002. Japanese encephalitis as an emerging virus: the emergence and spread of Japanese encephalitis virus in Australasia. Curr. Top. Microbiol. Immunol. 267: 49-73.
16. Markoff, L. 2000. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 18 Suppl 2: 26-32.
17. Nga, P.T., Del Carmen Parquet, M., Cuong, V.D., Ma, S.P., Hasebe, F., Inoue, S., Makino, Y., Takagi, M., Nam, V.S., and Morita, K. 2004. Shift in Japanese encephalitis virus (JEV) genotype circulating in northern Vietnam: implications for frequent introductions of JEV from Southeast Asia to East Asia. J. Gen. Virol. 85: 1625-1631.
18. Ohtaki, E., Matsuishi, T., Hirano, Y., and Maekawa, K. 1995. Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains). J. Neurol. Neurosurg. Psychiatr. 59: 316-317.
19. Oya, A. 1988. Japanese encephalitis vaccine. Acta Paediatr. Jpn. 30: 175-184.
20. Pigeon, J.G., Bohidar, N.R., Zhang, Z., and Wiens, B.L. 1999. Statistical models for predicting the duration of vaccine-induced protection. Drug Inform. J. 33: 811-819.
21. Plesner, A.M. 2003. Allergic reactions to Japanese encephalitis vaccine. Immunol. Allergy Clin. North Am. 23: 665-697.
22. Sugawara, K., Nishiyama, K., Ishikawa, Y., Abe, M., Sonoda, K., Komatsu, K., Horikawa, Y., Takeda, K., Honda, T., Kuzuhara, S., Kino, Y., Mizokami, H., Mizuno, K., Oka, T., and Honda, K. 2002. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 30: 303-314.
23. Tsai, T.F. 2000. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 18 Suppl 2: 1-25.
24. Van Damme, P., Thoelen, S., Cramm, M., De Groote, K., Safary, A., and Meheus, A. 1994. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J. Med. Virol. 44: 446-451.
25. Wiedermann, G., Kundi, M., Ambrosch, F., Safary, A., D'Hondt, E., and Delem, A. 1997. Inactivated hepatitis A vaccine: long-term antibody persistence. Vaccine 15(6/7): 612-615.
26. Wiens, B.L., Bohidar, N.R., Pigeon, J.G., Egan, J., Hurni, W., Brown, L., Kuter, B.J., and Nalin, D.R. 1996. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J. Med. Virol. 49: 235-241.
27. World Health Organization. 2006. Weekly epidemiological record. Wkly. Epidemiol. Rec. 81: 325-340.
28. World Health Organization. 2005. Weekly epidemiological record. Wkly. Epidemiol. Rec. 80: 241-248.
29. World Health Organization. 1998. Weekly epidemiological record. Wkly. Epidemiol. Rec. 73: 337-344.